These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 17597746)

  • 21. Amiloride is neuroprotective in an MPTP model of Parkinson's disease.
    Arias RL; Sung ML; Vasylyev D; Zhang MY; Albinson K; Kubek K; Kagan N; Beyer C; Lin Q; Dwyer JM; Zaleska MM; Bowlby MR; Dunlop J; Monaghan M
    Neurobiol Dis; 2008 Sep; 31(3):334-41. PubMed ID: 18606547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
    Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
    Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Placebo-controlled chronic high-frequency stimulation of the subthalamic nucleus preserves dopaminergic nigral neurons in a rat model of progressive Parkinsonism.
    Harnack D; Meissner W; Jira JA; Winter C; Morgenstern R; Kupsch A
    Exp Neurol; 2008 Mar; 210(1):257-60. PubMed ID: 18036524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levodopa toxicity and Parkinson disease: still a need for equipoise.
    Olanow CW; Obeso JA
    Neurology; 2011 Oct; 77(15):1416-7. PubMed ID: 21917774
    [No Abstract]   [Full Text] [Related]  

  • 25. How does Parkinson's disease begin? The role of compensatory mechanisms.
    Obeso JA; Rodriguez-Oroz MC; Lanciego JL; Rodriguez Diaz M
    Trends Neurosci; 2004 Mar; 27(3):125-7; author reply 127-8. PubMed ID: 15036875
    [No Abstract]   [Full Text] [Related]  

  • 26. Editor's note: does levodopa accelerate the pathologic process in Parkinson disease brain?
    Neurology; 2011 Oct; 77(15):1421. PubMed ID: 21917765
    [No Abstract]   [Full Text] [Related]  

  • 27. Is levodopa toxic? Insights from a brain bank.
    LeWitt PA; Dubow J; Singer C
    Neurology; 2011 Oct; 77(15):1414-5. PubMed ID: 21917780
    [No Abstract]   [Full Text] [Related]  

  • 28. Excessive dopamine neuron loss in progressive supranuclear palsy.
    Murphy KE; Karaconji T; Hardman CD; Halliday GM
    Mov Disord; 2008 Mar; 23(4):607-10. PubMed ID: 18163454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Calcium homeostasis, selective vulnerability and Parkinson's disease.
    Chan CS; Gertler TS; Surmeier DJ
    Trends Neurosci; 2009 May; 32(5):249-56. PubMed ID: 19307031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transplantation in Parkinson's disease: The future looks bright.
    Paul G; Ahn YH; Li JY; Brundin P
    Adv Exp Med Biol; 2006; 557():221-48. PubMed ID: 16955713
    [No Abstract]   [Full Text] [Related]  

  • 31. A glutathione deficit alters dopamine modulation of L-type calcium channels via D2 and ryanodine receptors in neurons.
    Steullet P; Lavoie S; Kraftsik R; Guidi R; Gysin R; Cuénod M; Do KQ
    Free Radic Biol Med; 2008 Mar; 44(6):1042-54. PubMed ID: 18206662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bursting in substantia nigra pars reticulata neurons in vitro: possible relevance for Parkinson disease.
    Ibáñez-Sandoval O; Carrillo-Reid L; Galarraga E; Tapia D; Mendoza E; Gomora JC; Aceves J; Bargas J
    J Neurophysiol; 2007 Oct; 98(4):2311-23. PubMed ID: 17715194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Study on the fiber connection of the substantia nigra].
    Masuda S
    Shinkei Kenkyu No Shimpo; 1968 Dec; 12(4):839-44. PubMed ID: 5753734
    [No Abstract]   [Full Text] [Related]  

  • 34. Progressive loss of dopaminergic neurons in the ventral midbrain of adult mice heterozygote for Engrailed1: a new genetic model for Parkinson's disease?
    Le Pen G; Sonnier L; Hartmann A; Bizot JC; Trovero F; Krebs MO; Prochiantz A
    Parkinsonism Relat Disord; 2008; 14 Suppl 2():S107-11. PubMed ID: 18585951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification and kainic acid-induced up-regulation of low-affinity p75 neurotrophin receptor (p75NTR) in the nigral dopamine neurons of adult rats.
    Wang YQ; Bian GL; Bai Y; Cao R; Chen LW
    Neurochem Int; 2008 Sep; 53(3-4):56-62. PubMed ID: 18639597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The origins of oxidant stress in Parkinson's disease and therapeutic strategies.
    Surmeier DJ; Guzman JN; Sanchez-Padilla J; Goldberg JA
    Antioxid Redox Signal; 2011 Apr; 14(7):1289-301. PubMed ID: 20712409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beating a dead horse: dopamine and Parkinson disease.
    Burke WJ
    Neurology; 2008 May; 70(22):2087. PubMed ID: 18505988
    [No Abstract]   [Full Text] [Related]  

  • 38. Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease.
    Wakamatsu M; Iwata S; Funakoshi T; Yoshimoto M
    J Neurosci Res; 2008 Feb; 86(3):640-6. PubMed ID: 17896793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse.
    Liu J; Wang YY; Liu L; Wang QD; Yuan ZY; Zhang ZX; Gu P; Wang MW
    Neurosci Lett; 2008 Dec; 448(2):184-8. PubMed ID: 18977411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overview of the extranigral aspects of Parkinson disease.
    Lim SY; Fox SH; Lang AE
    Arch Neurol; 2009 Feb; 66(2):167-72. PubMed ID: 19204152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.